221 related articles for article (PubMed ID: 27601519)
1. Dengue Dynamics and Vaccine Cost-Effectiveness Analysis in the Philippines.
Shim E
Am J Trop Med Hyg; 2016 Nov; 95(5):1137-1147. PubMed ID: 27601519
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Dengue Vaccination Programs in Brazil.
Shim E
Am J Trop Med Hyg; 2017 May; 96(5):1227-1234. PubMed ID: 28500811
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of dengue vaccination in ten endemic countries.
Zeng W; Halasa-Rappel YA; Baurin N; Coudeville L; Shepard DS
Vaccine; 2018 Jan; 36(3):413-420. PubMed ID: 29229427
[TBL] [Abstract][Full Text] [Related]
4. Dengue dynamics and vaccine cost-effectiveness in Brazil.
Durham DP; Ndeffo Mbah ML; Medlock J; Luz PM; Meyers LA; Paltiel AD; Galvani AP
Vaccine; 2013 Aug; 31(37):3957-61. PubMed ID: 23791696
[TBL] [Abstract][Full Text] [Related]
5. The Potential Cost Effectiveness of Different Dengue Vaccination Programmes in Malaysia: A Value-Based Pricing Assessment Using Dynamic Transmission Mathematical Modelling.
Shafie AA; Yeo HY; Coudeville L; Steinberg L; Gill BS; Jahis R; Amar-Singh Hss
Pharmacoeconomics; 2017 May; 35(5):575-589. PubMed ID: 28205150
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness and budget impact analyses of dengue vaccination in Indonesia.
Suwantika AA; Supadmi W; Ali M; Abdulah R
PLoS Negl Trop Dis; 2021 Aug; 15(8):e0009664. PubMed ID: 34383764
[TBL] [Abstract][Full Text] [Related]
7. An economic evaluation of vector control in the age of a dengue vaccine.
Fitzpatrick C; Haines A; Bangert M; Farlow A; Hemingway J; Velayudhan R
PLoS Negl Trop Dis; 2017 Aug; 11(8):e0005785. PubMed ID: 28806786
[TBL] [Abstract][Full Text] [Related]
8. Japanese encephalitis vaccination in the Philippines: A cost-effectiveness analysis comparing alternative delivery strategies.
Vodicka E; Zimmermann M; Lopez AL; Silva MW; Gorgolon L; Kohei T; Mooney J; Muhib F; Pecenka C; Marfin AA
Vaccine; 2020 Mar; 38(13):2833-2840. PubMed ID: 32085954
[TBL] [Abstract][Full Text] [Related]
9. Economic impact of dengue illness and the cost-effectiveness of future vaccination programs in Singapore.
Carrasco LR; Lee LK; Lee VJ; Ooi EE; Shepard DS; Thein TL; Gan V; Cook AR; Lye D; Ng LC; Leo YS
PLoS Negl Trop Dis; 2011 Dec; 5(12):e1426. PubMed ID: 22206028
[TBL] [Abstract][Full Text] [Related]
10. Cost-utility analysis of dengue vaccination in a country with heterogeneous risk of dengue transmission.
Orellano PW; Reynoso JI; Stahl HC; Salomon OD
Vaccine; 2016 Jan; 34(5):616-621. PubMed ID: 26724542
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of dengue vaccination in Yucatán, Mexico using a dynamic dengue transmission model.
Shim E
PLoS One; 2017; 12(4):e0175020. PubMed ID: 28380060
[TBL] [Abstract][Full Text] [Related]
12. Model-based assessment of public health impact and cost-effectiveness of dengue vaccination following screening for prior exposure.
España G; Yao Y; Anderson KB; Fitzpatrick MC; Smith DL; Morrison AC; Wilder-Smith A; Scott TW; Perkins TA
PLoS Negl Trop Dis; 2019 Jul; 13(7):e0007482. PubMed ID: 31260441
[TBL] [Abstract][Full Text] [Related]
13. Systematic review of health economic evaluation studies of dengue vaccines.
de Soárez PC; Silva AB; Randi BA; Azevedo LM; Novaes HMD; Sartori AMC
Vaccine; 2019 Apr; 37(17):2298-2310. PubMed ID: 30910406
[TBL] [Abstract][Full Text] [Related]
14. Current issues in the economics of vaccination against dengue.
Tozan Y
Expert Rev Vaccines; 2016; 15(4):519-28. PubMed ID: 26642099
[TBL] [Abstract][Full Text] [Related]
15. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines.
Capeding RZ; Luna IA; Bomasang E; Lupisan S; Lang J; Forrat R; Wartel A; Crevat D
Vaccine; 2011 May; 29(22):3863-72. PubMed ID: 21477675
[TBL] [Abstract][Full Text] [Related]
16. Projected Impact of Dengue Vaccination in Yucatán, Mexico.
Hladish TJ; Pearson CA; Chao DL; Rojas DP; Recchia GL; Gómez-Dantés H; Halloran ME; Pulliam JR; Longini IM
PLoS Negl Trop Dis; 2016 May; 10(5):e0004661. PubMed ID: 27227883
[TBL] [Abstract][Full Text] [Related]
17. The economic impact and cost-effectiveness of combined vector-control and dengue vaccination strategies in Thailand: results from a dynamic transmission model.
Knerer G; Currie CSM; Brailsford SC
PLoS Negl Trop Dis; 2020 Oct; 14(10):e0008805. PubMed ID: 33095791
[TBL] [Abstract][Full Text] [Related]
18. Projected costs associated with school-based screening to inform deployment of Dengvaxia: Vietnam as a case study.
Turner HC; Wills BA; Rahman M; Quoc Cuong H; Thwaites GE; Boni MF; Clapham HE
Trans R Soc Trop Med Hyg; 2018 Aug; 112(8):369-377. PubMed ID: 29982700
[TBL] [Abstract][Full Text] [Related]
19. Factors associated with the willingness of primary caregivers to avail of a dengue vaccine for their 9 to 14-year-olds in an urban community in the Philippines.
Reyes MSGL; Lee KMG; Pedron AML; Pimentel JMT; Pinlac PAV
Vaccine; 2020 Jan; 38(1):54-62. PubMed ID: 31668819
[TBL] [Abstract][Full Text] [Related]
20. Economic value of dengue vaccine in Thailand.
Lee BY; Connor DL; Kitchen SB; Bacon KM; Shah M; Brown ST; Bailey RR; Laosiritaworn Y; Burke DS; Cummings DA
Am J Trop Med Hyg; 2011 May; 84(5):764-72. PubMed ID: 21540387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
